MIRM - Mirum Pharmaceuticals GAAP EPS of -$1.94 misses by $1.14 revenue of $37.5M beats by $7.06M
2023-08-03 16:41:42 ET
- Mirum Pharmaceuticals press release ( NASDAQ: MIRM ): Q2 GAAP EPS of -$1.94 misses by $1.14 .
- Revenue of $37.5M (+114.3% Y/Y) beats by $7.06M .
- Total operating expenses were $61.8 million for the quarter ended June 30, 2023 in comparison to $48.9 million for the quarter ended June 30, 2022.
- As of June 30, 2023, Mirum had cash, cash equivalents, and short-term investments of $330 million.
- Closed upsized offering of $316.3 million aggregate principal amount of 4.00% convertible senior notes due 2029, including exercise of the initial purchasers’ option in full.
For further details see:
Mirum Pharmaceuticals GAAP EPS of -$1.94 misses by $1.14, revenue of $37.5M beats by $7.06M